Atanse (ah-TAHN-say) enables the treatment of devastating neurological diseases through pioneering intracerebral therapeutic delivery technology. We strive to develop stereotactic instruments that provide neurosurgeons with the highest possible accuracy and precision while minimizing associated trauma.
Atanse was chosen as the company's name because of one of our founder's history with the Dakota Sioux. Atanse is the Dakota word for "silent" and represents our stealth approach to restorative therapeutic delivery and our respect for the patients we help and for the power of effective neurosurgical intervention.
Chief Executive Officer
Mr. Kelly is an experienced engineer and entrepreneur, having bought and integrated seven companies and sold five. He has a BS/MS from the Massachusetts Institute of Technology and an MBA from Harvard University.
Chief Scientific Officer
Dr. Cunningham is the Director of the Laboratory for Neural Reconstruction at McLean Hospital and is affiliated with Harvard University Medical School. He has an MD from Harvard University and a PhD from the Massachusetts Institute of Technology.
Advisor & Board Member
Dr. Berger is a life sciences industry veteran with over 30 years of experience in regulation and reimbursement. He has a BA from Harvard University and a PhD from Boston University.
Alexandra Golby, MD, PhD
Associate Professor of Neurosurgery, Harvard Medical School
Brigham and Women’s Hospital, Boston, Massachusetts
Jeffrey Bruce, MD, PhD
Professor of Neurosurgery, Columbia Presbyterian Hospital, New York
Guido Nikkhah, MD, PhD
Vice Chairman, Dept of Stereotactic and Functional Neurosurgery, University Neurosurgery Clinic, Freiburg, Germany
Jens Christian Sorensen, MD, PhD
Chair, Department of Neurosurgery, Aarhus University Hospital, Denmark
Craig van Horne, MD, PhD
Chair, Department of Neurosurgery, St. Elizabeth’s Hospital, Brighton, Massachusetts